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Purpose: To compare the sensitivity of visual evoked potential (VEP) and 
electro-oculogram (EOG) tests in early detection of hydroxychloroquine 
(HCQ) retinal toxicity.
Patients and Methods: In this prospective cross-sectional study, 100 
consecutive patients (age range: 18 to 30 years) with juvenile rheumatoid 
arteritis (JRA) and a cumulative hydroxychloroquine dosage of at least 
200 gr were included.  In addition 100 healthy individuals with matched 
age and sex were included as controls. Ocular examinations including 
visual acuity testing, refractive errors measurement, applanation tonometry, 
slit lamp biomicroscopy fundus ophthalmoscopy and electrophysiological 
examinations (EOG and VEP) were performed in both groups. Scores 
of less than 1.8 for the Arden Index in EOG (AI), as well as less than 
4mv of P100 amplitude and more than 110ms of P100 latency in VEP 
were considered abnormal. 
Results: The mean cumulative dosage of HCQ among participants was 
262.4 ± 31.9 g (95 % CI: 256.1 to 268.8 g). The mean measurement of AI 
(EOG), P100 latency and amplitude of VEP were 1.8 ± 0.4, 112.7 ± 10.1 
ms and 3.7 ± 2.1 mv, respectively. There was a significant difference be-
tween case and control groups in all parameters (P < 0.001 for all). There 
was not any significant difference between AI (EOG), P100 latency and 
amplitude of VEP in detecting the ocular toxicity due to HCQ.
Conclusion: We conclude that AI (EOG), P100 amplitude and latency of 
VEP can all be useful parameters to detect HCQ retinal toxicity and we did 
not detect any difference between these methods. 
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Introduction
Chloroquine and  hydroxychloroquine (HCQ) are 
generations of 4-aminoquinoline antimalarial 
compounds (1), which are used to treat patients 
with rheumatoid arthritis (RA), systemic lupus 
erythematosus, dermatomyositis, Sjogren’s syn-
drome and other connective tissue diseases since 
the 1950s (2, 3). Although long term use of both 
has various side effects such as gastro-intestinal 
upset, skin rash, headache and eye abnormality, 
a major concern is their effect on different ocular 
structures including ciliary body involvement, 
crystalline lens opacity as well as retinopathy 
and keratopathy (2-6). Also major effects on retina 
causing permanent visual loss have been reported 
(7, 8). Therefore early detection of ocular side effects 
due to HCQ is necessary to prevent consequent 
serious ocular problems (9). Different ocular tests 
have been used to screen patients taking anti-
malarial drugs including visual acuity testing, 
dilated funduscopy, visual field testing, fundus 
photography, fluorescein angiography, color 
vision testing and electrophysiological tests, 
but their efficiency is controversial (10-13). Some 
studies have compared different visual tests in order 
to indicate the best test for screening (1, 4, 9, 10, 14). Some 
authors report that contrast sensitivity has the most 
sensitivity and efficiency compared with other 
considered tests (9), but others have found a P100 
latency of visual evoked potential (VEP) and 
photostress recovery time tests to be the best 
predictors in early stages of maculopathy, with the 
P100 latency of VEP being the best predictor in 
patients without ocular symptoms and fuduscopic 
lesions (4). A study by Neubauer et al. suggests 
a sensitive color vision test can be useful in 
screening of chloroquine retinopathy (10). Others 
have suggested the evaluation of central visual 
field as the best test for the early diagnosis of 
HCQ toxicity (2, 12). Although fluorescein angiography 
has been suggested to have less importance in 
diagnosis of early retinopathy, it is useful in patients 
who find visual field testing difficult (2, 15).
It has been observed that HCQ causes perifoveal 
changes in retinal pigmented epithelium layer 
(RPE) (4, 16) which induces abnormal readings in 
Electro-oculography (9) and visual evoked 
potential (16); therefore we decided to compare 
the sensitivity between these two electrophysiological 
tests, since they can assess visual function objectively 
against the other suggested subjective tests, so their 
results can be more reliable.
Electro-oculography (EOG) is a type of 
electrophysiologic test which measures the 
corneo-retinal standing potential that exists 
between the front and the back of the human eye. 
It does not measure the response to individual 
visual stimuli but shows the interaction between 
RPE and rod cells (17). EOG has been introduced 
as a sensitive test to indicate the functional 
disturbance due to storage of HCQ in RPE (18), 
although its usage is still controversial (19).  VEP 
refers to electrical potentials, initiated by either 
patterned or unpatterned visual stimuli, which are 
recorded from the scalp overlying the visual 
cortex (20). VEPs are used primarily to measure 
the functional integrity of the visual pathways 
from retina via the optic nerves to the visual 
cortex of the brain (20).
In the present study we compared VEP and 
EOG tests for detecting HCQ toxicity before 
the presence of ocular symptoms. 
Patients and Methods
In this prospective cross sectional study a total 
of 100 consecutive patients with and a history 
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of hydroxychloroquine usage were examined 
in Basir Eye Clinic, Tehran, Iran from June 2013 
to May 2014. The study was approved by the Lo-
cal ethics commitee, and a written consent was 
signed by all participants or their legal guardians 
before entering the study. The inclusion criteria 
was age of 17 to 30 years, a history of confirmed 
Juvenile rheumatoid arthritis (JRA), best correct-
ed visual acuity of  20/20 or better at both near 
and far distances, not having any obvious le-
sions on their funduscopic examinations, cumula-
tive dosage of at least 200 grams calculated based 
on the patients’ daily dose and duration. This was 
selected according to recommendation of the College 
of Ophthalmologists that suggests requirement of 
ophthalmic monitoring for patient with cumulative 
dosage higher than 200 grams (21, 22). The exclusion 
criteria were any other causes for macular chang-
es such as diabetes, central serous retinopathy, 
retinitis pigmentosa, age macular degeneration, 
any history of taking ophthalmic or systemic 
medications with an effect on the electrophysio-
logic tests readings, any history of ocular surgery, 
and other anterior or posterior segments ophthal-
mic diseases. The control group included 100 age 
and sex matched healthy individuals.
A comprehensive ocular examination including 
visual acuity testing, refractive errors measurement, 
applanation tonometry, slit lamp biomicroscopy as 
well as direct and indirect fundus ophthalmoscopy 
were performed on all cases and controls. 
Electrophysiological examinations were performed 
using EOG and VEP tests in both groups.
Electro-oculography (EOG)
Electro-oculography was performed in accordance 
with the standards of International Society for 
Clinical Electrophysiology of Vision (ISCEV). 
Pupil dilation was performed using 1 % tropicamide 
before pre-adaptation. Horizontal fixation targets 
were 30º apart and silver-silver chloride electrodes 
were placed according to ISCEV standards. Re-
cording was performed using a Jaeger-Toennies 
system (Hoechberg, Germany) and the Arden 
ratio (Arden quotient, AQ) between the lowest 
dark adapted point and highest light point was 
calculated. A score of less than 1.8 for the Arden 
Index (AI) was considered abnormal (9). 
Visual Evoked Potential (VEP)
VEP wave forms were recorded. The black and 
white size was 40 min of arc at a viewing distance 
of 1 m. In recording pattern VEP (PVEP), the ac-
tive electrode was positioned 2.5 cm above the inion 
(Oz), referenced to the center of the forehead with a 
ground electrode on the vertex of the head. All tests 
were performed with the subjects wearing their best 
refractive correction. The scores of less than 4 mv 
of  P100 amplitude and more than 110 ms of P100 
latency were considered abnormal (9).
Sample Size Calculation and Statistical Analysis
To have a power of 95 % to detect 1 unit difference 
in amplitude when the standard deviation of the 
amplitude was estimated to be 1.95 a sample size 
of 99 was needed. We entered 100 samples in each 
group. To describe data we used mean, standard 
deviation, median and range. To check the normal 
distribution of data we used Kolmogorov test with 
Q-Q plot and histogram. To evaluate the difference 
between two groups we used t-test, Mann-Whitney 
test and Chi-square test. Also, 95 % confidence 
interval (CI) was used to illustrate this difference. 
All statistical analysis was performed by SPSS 
(Version 17, SPSS Co., Chicago, IL). P values less 
than 0.05 were considered statistically significant.
Results
In the present study the readings of EOG and VEP 
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tests were compared in 100 patients with JRA (mean 
age: 23.5 ± 2.8 years) in order to determine the test 
with more sensitivity for screening of HCQ toxicity. 
Most participants (80 % of cases) were female. The 
mean cumulative dosage of HCQ among participants 
was 262.4 ± 31.9 g (95 % CI: 256.1 to 268.8 g). 
Table 1 summarizes the demographic characteristics of 
all participants. The mean measurement of  AI (EOG), 
P100 latency and amplitude of VEP were 1.8 ± 0.4, 
112.7 ± 10.1 ms and 3.7 ± 2.1 mv, respectively. There 
was a statistically significant difference between case 
and control groups in all parameters (P < 0.001 for all). 
Table 2 shows number of normal and abnormal 
readings in the case group according to criteria
indicated previously. A high number of our cases 
in all considered parameters were out of the normal 
limit. There was not any statistically significant 
difference between AI (EOG), P100 latency and 
amplitude of VEP in detecting the ocular toxicity 
due to HCQ. 
Figure 1 presents the percentage of normal and 
abnormal readings of AI of EOG, P100 latency and 
amplitude of VEP among cases. As shown 65 %, 
59 % and 49 % of patients were out of the normal 
limits according to P100 latency and amplitude of 
VEP as well as AI (EOG), respectively. 
Table 1: Demographic findings in the case and control groups.
PControlCaseTotalLevel
0.725  †23.4  ±  2.523.5  ±  2.823.4  ±  2.6 Mean  ±  SDAge
23 (17 to 28) 23 (18 to 30)23 (17 to 30)Median (range)
0.606 *77 (77.0 %)80 (80.0 %)157 (78.5 %)FemaleSex
23 (23.0 %) 20 (20.0 %) 43 (21.5 %)Male
 < 0.001 †2.2 ± 0.31.8 ± 0.42 ± 0.5Mean ± SDEOG(AI)
2.2 (1.4 to 3.1)1.8 (1.1 to 3)2.1 (1.1 to3.1)Median (range)
 < 0.001 §102.1 ± 4.1112.7 ± 10.1107.4 ± 9.4Mean ± SDLatency
102 (92 to 112)115 (94 to 135)104 (92 to135)Median (range)
 < 0.001 §6.2 ± 1.63.7 ± 2.14.9 ± 2.3Mean ± SDAmplitude
6 (1 to 10)3 (1 to 8)5 (1 to 10)Median (range)
        EOG: electro-oculogram; AI: arden index; SD: standard deviation; P: probability
          † Based on t-test.
          * Based on Chi-Square test.
          § Based on Mann-Whitney test.
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Figure 1: The distribution of normal and abnormal readings in EOG (AI) as well as latency (VEP) and amplitude 
(VEP) among patients.
Table 2: The percentage of normal and abnormal readings in EOG and VEP of patients and controls.
         
UpperLowerControlCase
94 (94.0 %)51 (51.0 %)NormalEOG (AI)
 <  0.00153.8 %32.2 %43.0 %6 (6.0 %)49 (49.0 %)Abnormal
98 (98.0 %)35 (35.0 %)NormalLatency
 <  0.00172.7 %53.3 %63.0 %2 (2.0 %)65 (65.0 %)Abnormal
96 (96.0 %)41 (41.0 %)NormalAmplitude





 EOG: electro-oculogram; AI: arden index; CI: confidence interval; P: probability.
          * Based on Chi-Square test.
          ** Based on Cochran test.        
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Discussion
Nowadays HCQ is used widely in order to 
manage connective tissue and skin disorders 
due to lower side effects compared to chloroquine 
(2). It is necessary to perform regular eye screening 
programs using the best test possible with more 
sensitivity and a good power for early detection 
and prevention of HCQ ocular toxicity (4). We only 
entered patients with JRA in the age range of 17 
to 30 years old to eliminate the effect of senile 
changes like the accumulation of lipofuscein 
deposits that might affect the electrophysiological 
readings. 
Although the American Academy of Ophthal-
mology guidelines considers patients with HCQ 
duration usage of less than 5 years to be at a 
lower risk of toxicity (12), majority of our patients 
showed readings out of the normal limitations 
(Table 2). Bishara et al. studied patients who 
took HCQ for periods ranging from 1 to 9 years 
and found that EOG cannot detect the early ocu-
lar toxicity as good as contrast sensitivity test (9). 
In a study Neubauer et al. (10) compared EOG 
versus color vision test to indicate the one with 
more sensitivity to evaluate early ocular changes 
due to chloroquine and HCQ usage. They found 
color vision test to be a more sensitive test for 
screening, but EOG showed little diagnostic value 
in this regard. 
The mean P100 latency was 112.7 ± 10.1 ms among 
our cases and it was significantly higher than con-
trols (P < 0.001) similar to other studies (1, 4, 9). Sixty 
five percent of our cases who used HCQ had P100 
latency higher than 110 ms. It means that HCQ 
can prolong the P100 latency of VEP test which 
is the most reliable indicator of abnormality since 
it is least effected by patient cooperation and tech-
nical factors (20). Heravian et al. (4) have indicated 
P100 latency as the best predictor of HCQ ocular 
toxicity in patients without ocular symptoms and 
fundoscopic changes and have reported that it can 
predict early stages of HCQ maculopathy. 
Fifty nine percent of our cases had abnormal P100 
amplitude, the mean was 3.7 ± 2.1 mv and it was 
significantly lower than controls (P < 0.001). How-
ever Heravian et al. found no statistically signifi-
cant difference between P100 amplitude in their 
case and control groups with the age range of 20 
to 50 years old (4). This difference can be attributed 
to the fact that amplitude is an indicator of clini-
cal abnormality and is more prone to be affected 
by technical factors, patients› fixation, cooperation 
and alertness (20). 
Bartel et al. 14 believed that VEP is not a suitable 
test for screening of HCQ and Bishara et al. (9) have 
stated that VEP is unable to detect ocular toxicity 
due to HCQ as good as contrast sensitivity test. We 
found that VEP and EOG can both determine early 
changes due to HCQ ocular toxicity in more than 
half of our patients. 
Conclusion
We conclude that AI (EOG), P100 amplitude 
and latency of VEP can all be useful parameters 
to detect HCQ retinal toxicity and we did not 
detect any difference between these methods. 
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